Motixafortide - Biokine Therapeutics/BioLineRx
Alternative Names: 4F-Benzoyl-TN14003; APHEXDA; BKT-140; BL-8040; GFH-168; TF-14016; TN-14003Latest Information Update: 04 Jun 2024
At a glance
- Originator Kyoto University
- Developer Biokine Therapeutics; BioLineRx; Genentech; Merck & Co
- Class Antianaemics; Antineoplastics; Cyclic peptides; Peptides
- Mechanism of Action Apoptosis stimulants; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Stem cell mobilisation
- Phase II Acute myeloid leukaemia; Aplastic anaemia; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I/II Gastric cancer
- No development reported Adult respiratory distress syndrome
- Discontinued Chronic myeloid leukaemia; Thrombocytopenia
Most Recent Events
- 30 May 2024 BioLineRx in collaboration with St. Jude Children's Research Hospital plans a phase I trial for Sickle cell disease in the next few months (SC)
- 24 May 2024 Efficacy and pharmacodynamics data from the phase II CheMo4METPANC trial in Pancreatic cancer released by BioLineRx
- 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)